Larimar Therapeutics
CompanyUnited StatesFounded 2005
Larimar Therapeutics develops one asset, in phase 3 (Nomlabofusp in Friedreich ataxia). Mostly protein or enzyme acting on Oxidative stress and ROS signalling, oxidative phosphorylation and Mitochondrial biogenesis (PGC-1α); based in the United States, founded in 2005.
- 1
- Asset
- Furthest stage
- Phase 3
- Raised
- US$182.1m
- 0
- Trials
- 0
- Signals
Pipeline
1Delivers human frataxin into mitochondria, where it is processed to mature frataxin and becomes active in mitochondrial metabolism.
Phase 3, Protein or enzyme, Oxidative stress and ROS signalling, Oxidative phosphorylation, Friedreich ataxia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Funding rounds and grants2
- Deals5
- People13
- Signals1
- Similar companies6